Switching from Intravitreal Ranibizumab to Bevacizumab for
Age-Related Macular Degeneration
Figure 3
The mean foveal retinal thickness (FRT) at the followup visits and prior to switching treatment. A significant difference was noted at six weeks, six months, and at the final visit compared with the value before the switch (*The Wilcoxon signed-rank test: ).
